Trial Profile
Phase I trial of heat shock protein peptide complex-96 (HSPPC-96; vitespen; NP-150) vaccine in paediatric patients with brain tumours.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 14 Mar 2011
Price :
$35
*
At a glance
- Drugs Vitespen (Primary)
- Indications Brain cancer
- Focus Therapeutic Use
- 14 Mar 2011 New trial record